ABCB1基因多态性对乳腺癌患者多西他赛血液学毒性的影响

Effects of ABCB1 gene polymorphism on hematological toxicity of docetaxel in breast cancer patients

目的探讨乳腺癌患者ABCB1(3435 T>C、2677 T>G)基因多态性对多西他赛血液学毒性作用的影响,旨在为临床安全用药提供参考。方法回顾性分析77例乳腺癌患者资料,根据化疗方案的不同分为两组:实验一组(多西他赛联合环磷酰胺)和实验二组(多西他赛联合表柔吡星)。应用六周期化疗方案,分析两组不同基因型对应患者出现骨髓抑制情况的差异。计数资料比较采用χ~2检验,P<0.05为差异有统计学意义。结果 ABCB1(3435T>C)野生纯合型(TT型)乳腺癌患者应用多西他赛发生血液学毒性的风险高于其他基因型,差异有统计学意义(P<0.05)。ABCB1(2677T>G)不同基因型患者发生血液学毒性风险的差异无统计学意义(P>0.05)。结论乳腺癌患者应用多西他赛时可以通过检测ABCB1(3435T>C)的基因型,在一定程度上可以预知患者的血液学毒性风险,从而调整患者治疗方案,实现多西他赛的个体化治疗。

Objective To investigate the effects of ABCB1 gene polymorphism on hematological toxicity of docetaxel in breast cancer patients, providing reference for clinical safety of drugs.Methods The data of 77 breast cancer patients were analyzed retrospectively, and then divided into two groups：groupⅠ（docetaxel combined with cyclophosphamide） and group Ⅱ（docetaxel combined with epirubicin） according to therapy plan. After the application of six cycles, and then differences of myelosuppression between patients with different genotypes in two groups were compared.Enumeration data were compared by χ^2 test.P0.05 was considered statistically significant.Results The risk of hematology toxicity in the breast cancer patients with ABCB1（3 435 t〉 C） TT after the application of docetaxel was higher than other genotypes. The difference was statistically significant（P〈0.05）. The difference of hematology toxicity in the breast cancer patients with ABCB1（2 677 T〉G）was not statistically significant（P〉0.05）.Conclusion In breast cancer patients, we can predict the patient＇s hematological toxicity to a certain extent by detecting the genotype of ABCB1（3 435 T〉C） in docetaxel, so as to adjust the treatment plan and to realize the individualized treatment.